Dr Zachary Charles Junga, MD | |
Landstuhl Regional Medical Center, Unit 33100, Apo, AE 09180 | |
(314) 590-6015 | |
Not Available |
Full Name | Dr Zachary Charles Junga |
---|---|
Gender | Male |
Speciality | Internal Medicine - Gastroenterology |
Location | Landstuhl Regional Medical Center, Apo, Armed Forces Europe |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1134544877 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RG0100X | Internal Medicine - Gastroenterology | 0101259138 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Zachary Charles Junga, MD Landstuhl Regional Medical Center, Unit 33100, Apo, AE 09180 Ph: () - | Dr Zachary Charles Junga, MD Landstuhl Regional Medical Center, Unit 33100, Apo, AE 09180 Ph: (314) 590-6015 |
News Archive
The incidence of human bladder cancer has greatly increased over the last few decades, with more than 60,000 new cases diagnosed each year in the United States alone, and now represents the 4th most common malignancy in men and the 10th most common in women, according to background information in the article.
Idera Pharmaceuticals, Inc. today announced the publication of data from studies of a dual agonist of Toll-like Receptor 7 and TLR8 in preclinical models of cancer. The Company created this first-in-class RNA-based dual agonist of TLR7 and TLR8 through its chemistry-based approach to identifying novel TLR-targeted drug candidates.
HealthLeaders-InterStudy, a provider of managed care industry intelligence, reports hordes of area physicians are venturing enthusiastically into ownership of general acute-care hospitals with the vow to treat a full range of patients.
Alkermes, Inc. today announced that it has submitted a supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) to the U.S. Food and Drug Administration (FDA) for approval as a treatment for opioid dependence. The company requested a priority review for its sNDA and if granted by the FDA, it would mean a six month review timeline.
› Verified 7 days ago
Dr. Revati Komandur, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: Landstuhl Regional Medical Center, Unit 33100, Apo, AE 09180 Phone: 314-590-7351 | |
Brian Mccarthy, D.O. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: Unit 33100, Apo, AE 09180 Phone: 314-590-4515 | |
Dr. Alexander Sturgis Macomber Fye, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: Raf Lakenheath 48 Mdg/sghc, Unit 5115, Apo, AE 09461 Phone: 163-852-8118 | |
Dr. Mark Anderson, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: Spangdahlem Afb, Apo, AE 09126 Phone: 496-561-618333 | |
Dr. Bryon James Davis, DO Gastroenterology Medicare: Medicare Enrolled Practice Location: Landstuhl Regional Medical Center, Unit 33100, Apo, AE 09180 Phone: 314-590-5836 | |
Dr. Mary Jean Hamel, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: Kemri Cdc Research Station, Unit 64112, Apo, AE 09831 Phone: 254-722-772616 |